Table 1.

Demographic and Baseline Characteristics of Patients With Either C-CD or SB-CD

	C-CD (n = 11)	SB-CD (n = 8)	P value
Mean age at diagnosis, y	10.9	11	.95
Sex, % female	36.3	25	1
Ethnicity, % Caucasian	72.7	87.5	.6
Paris location, %
L1	0	50	.018
L2	54.5	0	.018
L3	45.5	25	.63
L4a	18.2	37.5	.6
L4b	0	100	.0001
Paris behavior, %
B1	45.5	12.5	.177
B2	27.2	62.5	.18
B3	18.2	0	.485
B2/B3	9.1	25	.546
Perianal disease, % yes	36.4	12.5	.338
Presence of granulomas, % yes	33.3 (2/6)	33.3 (3/9)	1
Surgical intervention required, % yes	54.5	75	.633
Surgery in first 2 years, % yes	33.3 (2/6)	50 (3/6)	1
Type of surgery, %	n = 6	n = 6
Partial colectomy	50	50	1
Total colectomy	33.3	0	.455
Ileocecotomy	0	16.7	1
Enterectomy	16.7	66.7	.242
Small-bowel diversion only	16.7	0	1
Biologic agents used before surgery, %	n = 6	n = 6
Infliximab	100	66.7	.455
Adalimumab	83.3	33.3	.242
Ustekinumab	16.7	16.7	1
Vedolizumab	16.7	0	1
Biologic agents used in nonsurgical patients, %	n = 5	n = 2
Infliximab	80	100	.49
Adalimumab	60	0	.429

C-CD, colon-predominant Crohn’s disease; SB-CD, small-bowel–predominant Crohn’s disease.